TrialsgrambetaRCTs are beautiful

ACCORD

2008

Action to Control Cardiovascular Risk in Diabetes

In 10,251 patients with long-standing T2DM and CV disease or risk factors, intensive glucose control targeting HbA1c <6.0 % increased all-cause mortality compared with standard control (7.0–7.9 %).

Result

Efficacy: Non-fatal MI, non-fatal stroke or CV deathHR 0.90 (95% CI 0.78-1.04) · P = 0.16

Safety: All-cause mortalityHR 1.22 (95% CI 1.01-1.46) · P = 0.04

Below 1 favours intensive glucose control targeting HbA1c <6.0 %, above 1 favours standard control (7.0–7.9 %).

Original publication
Subtopic
Intensive vs standard glycaemia
Design
RCT, stopped early at 3.5 yr
Relevance
Practice-defining: a trial the field needs to know.
Source
ACCORD Study Group. N Engl J Med. 2008;358(24):2545-2559.doi 10.1056/NEJMoa0802743

Discussion & critique

Established the harm of over-aggressive glucose-lowering in long-standing T2DM and underpins individualised HbA1c targets.

Discussed in podcasts